Recent NewsArchiveVERTIFLEX®

Partners Group to Acquire PCI Pharma Services, A Leading Global Provider of Outsourced Pharmaceutical Services                                                                                                         June 1, 2016

Jazz Pharmaceuticals and Celator Pharmaceuticals Announce Agreement for Jazz Pharmaceuticals to Acquire Celator for $30.25 Per Share                                                         May 31, 2016                                                  

BTG plc acquires Galil Medical, a leader in cryoablation                                                           May 6, 2016

Celator Announces Phase 3 Trial for VYXEOS (CPX-351) in Patients With High Risk Acute Myeloid Leukemia Demonstrates Statistically Significant Improvement in Overall Survival
March 14, 2016

ICALAmerican Medical Association Creates New Category 1 Code for Torax Medical's LINX Procedure to Treat Gastroesophageal Reflux Disease                                                               November 15, 2015

VERTIFLEX® Announces Two Significant Reimbursement Milestones to Expand Market Opportunity For Superion Interspinous Spacer VERTIFLEX®                                                     November 10, 2015

Celator (R) Pharmaceuticals Announces Positive Induction Response Results from Phase 3 Study of CPX-351 in Patients with High-Risk (Secondary) Acute  Myeloid Leukemia
June 24, 2015

Tioga Pharmnaceuticals Announces Initiation of Phase 2 Clinical Study of Asimadoline in Patients with Pruritus Associated with Atopic Dermatitis
June 11, 2015

VertiFlex(R), Inc. Announces FDA PMA Approval for the Superion(R) Interspinous Spacer
May 26, 2015

Teva Reinforces Leadership Position in CNS with Acquisition of Auspex
March 30, 2015

Boston Scientific Receives FDA Approval for Watchman (TM) Left Atrial Appendage Closure Device
March 13, 2015

VertiFlex(R), Inc. Announces FDA Advisory Panel Support for the Superion(R) Interspinous Spacer
February 23, 2015

Invitae Announces Pricing of Initial Public Offering of Common Stock
February 11, 2015

CAS Medical Systems Announces Pricing of Public Offering of Common Stock
February 11, 2015

Auspex Pharmaceuticals Completes Enrollment in a Pivotal Clinical Trial of 809 in Tardive Dyskinesia
February 3, 2015

Auspex Announces Pricing of Follow On Offering
January 23, 2015

Celator(R) Pharmaceuticals Receives FDA Fast Track Designation for CPX-351 for the Treatment of Elderly Patients with Secondary Acute Myeloid Leukemia
January 20, 2015

Auspex Pharmaceuticals Receives FDA Orphan Drug Designation of SD-809 for Treatment of Tourette Syndrome in the Pediatric Population
January 14, 2015

Auspex Pharmaceuticals Announces SD-1077 Program for the Potential Treatment of Parkinson's Disease and Related Movement Disorders
January 12, 2015

CASMED Appoints Paul Molloy to its Board of Directors
January 5, 2015

Auspex Announces Topline Results from Registration Trial of SD-809 for Chorea Associated with Huntington's Disease
December 16, 2014

Auspex Pharmaceuticals Receives FDA Orphan Drug Designation of SD-809 for Treatment of Huntington's Disease
November 6, 2014

Celator(R) Pharmaceuticals Announces Phase 3 Clinical Study of CPX-351 Achieved Target Enrollment in High Risk (Secondary) Acute Myeloid Leukemia
October 27, 2014

Invitae Completes $120 Million Series F Financing
October 13, 2014

Pfizer Completes Acquisition of InnoPharma
September 25, 2014

PCI Announces Definitive Agreement to Acquire Penn Pharma
July 28, 2014

Clarus Therapeutics Expands Board of Directors With Appointment of Two Pharmaceutical Industry Veterans
July 21, 2014

Auspex Pharmaceuticals Initiates Pivotal Phase 2/3 Clinical Trial for SD-809 in Tardive Dyskinesia
July 17, 2014

Pfizer to Acquire InnoPharma, Inc.
July 16, 2014

Auspex Pharmaceuticals Announces Data From Interim Analysis of ARC-HD Switch Trial Demonstrating Clinical Activity of SD-809
June 23, 2014

Clarus Therapeutics Secures $31.5 Million in Financing
June 12, 2014

Celator(R) Pharmaceuticals Announces Publication of Positive Phase 2 Data With CPX-351 in Acute Myeloid Leukemia Patients 
May 27, 2014

CASMED Receives FDA Approval for FORE-SITE ELITE in Non-Cerebral Tissue
May 7, 2014

Auspex Pharmaceuticals Added To The Russell 2000® Index
March 31, 2014

Auspex Announces Completion of Public Offering and Exercise In Full Of Underwriters' Over-Allotment Option
February 10, 2014

Auspex Announces Pricing of Initial Public Offering
February 5, 2014

VertiFlex(R), Inc. Announces Decision by the Centers for Medicare & Medicaid Services
January 14, 2014

Clarus Therapeutics Submits New Drug Application for Rextoro (formerly CLR-610) for the treatment of Low Testosterone 
January 13, 2014

Celator(R) Pharmaceuticals Reaches 50% Enrollment for CPX-351 Phase 3 Study 
January 9, 2014

Auspex Raises $35 Million And Appoints Industry Veteran Gerald Proehl To Its Board of Directors
January 8, 2014